Morgan Stanley V Tv Therapeutics Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.72 - $1.01 $1 - $2	-2 Reduced 0.01%	33,442 $27,000
Q4 2022 Feb 14, 2023	BUY	$0.66 - $40.8 $0 - $40	1 Added 0.0%	33,444 $22,000
Q2 2022 Oct 27, 2022	SELL	$0.39 - $0.84 $671 - $1,447	-1,723 Reduced 4.9%	33,443 $25,000
Q2 2022 Aug 15, 2022	SELL	$0.39 - $0.84 $671 - $1,447	-1,723 Reduced 4.9%	33,443 $25,000
Q1 2022 Oct 27, 2022	BUY	$0.51 - $1.0 $878 - $1,723	1,723 Added 5.15%	35,166 $25,000
Q1 2022 May 13, 2022	SELL	$0.51 - $1.0 $87,764 - $172,087	-172,087 Reduced 83.03%	35,166 $25,000
Q4 2021 Feb 14, 2022	BUY	$0.95 - $1.69 $121,940 - $216,925	128,358 Added 162.69%	207,253 $206,000
Q3 2021 Nov 15, 2021	BUY	$1.53 - $2.22 $120,709 - $175,146	78,895 New	78,895 $121,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.77B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.